Currently, it costs a public bank approximately USD $2,000 to collect, test, and process a unit of cord blood for storage. In order to accept donations at no cost, public banks require income to support themselves. This income can come from federal funding, the profit margin of private banking, or from selling donated cord blood units for research. Alternatively, it can come from a combination of the above.
The global cord blood industry experienced strong growth from the early 1990’s through the late 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space.
Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation, cutting the global number of cord blood banks by approximately half.
Over the past decade, the cord blood industry has witnessed substantial consolidation, particularly within the United States, Europe, Asia, and Latin America. [Read more…]
Looking to make a decision about U.S. cord blood banks? The sortable list below includes all Public, Private, and Hybrid Cord Blood Banks in the United States.
- Private cord blood banks store cord blood units for private use by individual families (for a fee)
- Public cord blood banks store cord blood donations for public use (free of cost)
- Hybrid cord blood banks offer both public and private cord blood banking services
For those analyzing cord blood market dynamics, Cord Blood Registry (CBR) is the largest U.S. cord blood bank with over 925,000 cord blood and tissue units in storage. The next two largest cord blood banks within the U.S. are Viacord and Cryo-Cell.
In aggregate, there are a large number of public and private banks of varying sizes, as shown in the table below.
Over the past 30 years, cord blood and cord tissue have gained popularity and commercial traction due to the valuable stem cells they contain. According to ClinicalTrials.gov, there are over 1,360 clinical trials evaluating the use of cord blood and tissue-derived cells. These studies typically leverage unmanipulated whole cord blood (total nucleated cells/TNC), mononuclear cells (MNC), or cord blood-derived mesenchymal stem cells (MSCs). [Read more…]
Americord Registry announces the addition of exosome banking to their suite services, becoming the first company in the United States to do so.
NEW YORK, NEW YORK, US, October 11, 2022 – Americord Registry®, a leader in the cord blood industry, announced the addition of exosome banking to their suite of family-focused services, becoming the first private biobanking company in the United States to do so. Exosomes are tiny, extracellular vesicles that initiate cell-to-cell communication by shuttling cellular components to other cells. Pre-clinical research has shown that exosomes may regulate immune responses, wound healing, and cell growth and development. [Read more…]